Repurposing Drugs to Modulate DNA Repair Pathways in CRISPR Genome Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that can occur spontaneously or be intentionally introduced by genome editing technologies such as CRISPR-Cas9. The cellular response to DSBs involves several repair pathways, notably non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway produces distinct repair outcomes, with implications for genome integrity and editing precision. While CRISPR-based technologies are revolutionizing disease modeling and therapy, the unpredictability of DSB repair outcomes remains a significant barrier to their clinical translation. The reference study (Macak et al., 2025) addresses whether clinically approved drugs can be repurposed to control the choice and efficiency of DSB repair pathways, ultimately enhancing the performance and safety of genome editing applications.

Key Innovation from the Reference Study

The key innovation of this work lies in its high-throughput, systematic screen of more than 7,000 FDA-approved compounds to identify modulators of DSB repair outcomes during CRISPR genome editing in human induced pluripotent stem cells (hiPSCs). By directly linking pharmacological intervention to the frequency and type of genetic edits produced, the study pioneers an actionable framework for precision control over genome editing outcomes. Notably, the authors not only map drugs that enhance or inhibit NHEJ, MMEJ, and HDR, but also highlight compounds that induce synthetic lethality in the context of pathway inhibition. This approach opens new avenues for both therapeutic genome editing and targeted cancer treatments where DNA repair vulnerabilities can be exploited.

Methods and Experimental Design Insights

The experimental workflow centers on CRISPR-mediated editing of the FRMD7 locus in 409B2 hiPSCs, which stably express doxycycline-inducible Cas9 (iCRISPR). During genome editing, cells are exposed to individual drug conditions, after which cell viability is assessed by resazurin fluorescence, and editing outcomes are quantified by Illumina sequencing. The mutational signatures are classified as precise edits (HDR), small indels via NHEJ, or larger deletions via MMEJ. Each drug’s effect on repair pathway distribution and cell survival is determined in comparison to DMSO controls (Macak et al., 2025).

Additionally, gene silencing experiments targeting ESR2 and AOX1 are conducted to dissect protein-level influences on DNA repair, revealing synergistic effects when ESR2 is suppressed alongside NHEJ inhibition. The robustness of the screen allows for the identification of drugs that shift repair outcomes in favor of either precise knock-in (HDR/SSTR) or gene disruption (NHEJ/MMEJ), as well as those that sensitize cells to synthetic lethality upon pathway blockade.

Protocol Parameters

• Cell line: Human iPSC line 409B2 expressing inducible Cas9.
• Drug treatment: 1 compound per well, applied during CRISPR editing (screen included >7,000 FDA-approved drugs).
• CRISPR target: FRMD7 locus, edited with guide RNA during drug exposure.
• Viability assay: Resazurin fluorescence post-recovery.
• Editing outcome quantification: Illumina sequencing; classification into HDR, NHEJ, and MMEJ outcomes.
• Gene silencing (for mechanistic studies): siRNA targeting ESR2 and AOX1.
• Key readouts: Relative frequency of each repair outcome vs. DMSO control; cell survival rates.

Core Findings and Why They Matter

1. Drug Modulation of Repair Pathways: The study identifies numerous clinically safe drugs that can be repurposed to modulate DSB repair outcome distributions, including both inhibitors and enhancers of NHEJ, MMEJ, and HDR. This pharmacological control enables more predictable editing outcomes, which is essential for therapeutic genome editing and disease modeling (Macak et al., 2025).

2. Synergistic Mechanisms: Targeting ESR2 in conjunction with NHEJ inhibition yields a mean 4.6-fold increase in HDR rates, underscoring the potential for combinatorial approaches to selectively favor precise editing. This is especially relevant for applications such as correction of pathogenic point mutations or insertion of therapeutic genes.

3. Synthetic Lethality Strategies: The screen uncovers drugs that induce synthetic lethality when NHEJ or HDR is blocked, presenting new candidates for precision oncology. Such strategies exploit repair deficiencies unique to cancer cells, sparing healthy tissues and providing a rationale for patient-tailored therapies.

4. Practical Implications: The data suggest that the choice of pharmacological modulator can be tailored to the desired outcome: enhancing knock-in efficiency, minimizing unwanted deletions, or sensitizing cells for selective cell death. For genome editing in disease models or cellular therapies, this level of control could improve efficacy and safety profiles.

Comparison with Existing Internal Articles

The findings of the reference study resonate with themes explored in several internal resources focused on DNA repair modulation and calcium signaling. For example, "Drug Repurposing for DNA Repair Pathway Control in CRISPR Editing" discusses a similar high-throughput screening approach for pathway control, reinforcing the strategy of using clinically approved compounds to fine-tune genome editing outcomes.

Moreover, compounds such as dantrolene sodium salt, a well-characterized ryanodine receptor antagonist, have been shown to support advanced disease modeling and genome editing workflows by precisely modulating intracellular calcium release (see internal article). This is especially relevant since calcium signaling can intersect with DNA damage response pathways, and calcium modulators could conceivably be integrated into multi-modal editing strategies. The internal articles highlight the reproducibility and mechanistic specificity of tools like dantrolene sodium salt for applications requiring fine control of cellular physiology during genome engineering.

Limitations and Transferability

While the reference study demonstrates robust modulation of repair outcomes in human iPSCs, several limitations merit consideration. First, the effects of individual drugs may vary across cell types, genomic loci, or under different editing contexts. The screen was performed in a single cell line and at a single target locus, so generalizability to primary cells or in vivo models should be validated. Second, long-term consequences of repair pathway manipulation—including potential genotoxicity or off-target effects—remain to be fully characterized. Finally, while the identification of synthetic lethality candidates is promising for precision oncology, translation will require rigorous preclinical validation to assess efficacy and safety in tumor versus normal tissues. The study provides a foundational map but recommends that pathway modulation strategies be carefully optimized for each experimental system.

Research Support Resources

To facilitate similar research workflows, high-purity reagents that enable precise modulation of cellular pathways are essential. For example, Dantrolene, sodium salt (SKU B6329) from APExBIO is a nanomolar-potency ryanodine receptor antagonist that supports calcium signaling modulation and disease modeling. Its demonstrated calmodulin-dependent specificity and reproducibility make it a practical choice for studies intersecting genome editing and cellular physiology. For protocol guidance and troubleshooting, researchers can consult relevant internal articles on precision ryanodine receptor antagonist workflows. As with any DSB repair modulator, careful validation of effects in the intended system is recommended.